Schizophrenia News and Research

Latest Schizophrenia News and Research

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor.

16 Dec 2009

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that it has initiated a Phase I clinical trial of its lead compound GLYX-13 and has successfully dosed the first subjects in the study.

16 Dec 2009

Alexza Pharmaceuticals submits its NDA for Staccato loxapine to FDA

Alexza Pharmaceuticals, Inc. today announced that it has submitted its New Drug Application (NDA) for Staccato® loxapine (AZ-004) to the US Food and Drug Administration (FDA).

15 Dec 2009

ZYPREXA RELPREVV approved by FDA

The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company announced today.

14 Dec 2009

New biosensors show how schizophrenia drugs alter brain chemistry

Scientists have resolved a question about how a popular class of drugs used to treat schizophrenia works using biosensors that reveal previously hidden components of chemical communication in the brain.

14 Dec 2009

Targacept commences TC-5619 Phase 2 study of cognitive dysfunction in schizophrenia

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR TherapeuticsTM, today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia.

10 Dec 2009

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week.

10 Dec 2009

Eli Lilly provides financial guidance for 2010

At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.

10 Dec 2009

CMHA calls to extend Employment Insurance benefits and Pharmacare program for mentally-ill patients

Canadian Mental Health Association (CMHA), National supports several of the recommendations of "In From The Margins: A Call to Action on Poverty, Housing and Homelessness", Report of the Subcommittee on Cities of the Standing Senate Committee on Social Affairs, Science and Technology tabled yesterday in Ottawa.

10 Dec 2009

ACNP 2009 to feature research on PTSD, biomarkers for schizophrenia and treatment for gambling addiction

The 2009 American College of Neuropsychopharmacology Annual Meeting will feature innovative research on PTSD, biomarkers for schizophrenia and treatment for gambling addiction.

10 Dec 2009

NYSE Amex to delist Cortex Pharmaceuticals

Cortex Pharmaceuticals, Inc. announced that it has received notification from the NYSE Amex LLC indicating that, due to the Company’s non-compliance with certain continued listing standards as previously reported, the Exchange intends to delist the Company’s common stock from the NYSE Amex effective as of the close of business on Friday, December 11, 2009.

9 Dec 2009

Successful reduction in the levels of aggregated Abeta with GSMs

EnVivo Pharmaceuticals today reported the successful reduction in the levels of aggregated Abeta or Beta-Amyloid in an aged transgenic model (Tg2576) of Alzheimer's disease with its lead gamma-secretase modulator (GSM) EVP-0962. The aggregated Abeta, containing predominately oligomeric and larger Abeta fibrillar species, is considered to be the toxic entity in Alzheimer's disease.

9 Dec 2009

Psychological trauma leaves a trail of damage in a child's brain, reveal scientists

Psychological trauma leaves a trail of damage in a child's brain, say scientists at the Stanford University School of Medicine and Lucile Packard Children's Hospital. Their new study gives the first direct evidence that children with symptoms of post-traumatic stress suffer poor function of the hippocampus, a brain structure that stores and retrieves memories. The research helps explain why traumatized children behave as they do and could improve treatments for these kids.

9 Dec 2009

Two Brown University faculty members receive federal funding for new neuroscience research projects

Two Brown University faculty members have received federal funding for innovative new neuroscience research projects focusing on brain development in infants and bipolar disorder in children.

7 Dec 2009

Janssen-Cilag submits MAA to the European Medicines Agency for paliperidone palmitate

Elan Drug Technologies, a business unit of Elan Corporation, plc announced that Janssen-Cilag has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency for paliperidone palmitate for the treatment of Schizophrenia.

4 Dec 2009

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

The U.S. Food and Drug Administration (FDA) today approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old.

4 Dec 2009

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur more often in people who said they had been diagnosed with epilepsy versus those without an epilepsy diagnosis, according to a survey of approximately 173,000 households across the U.S.

4 Dec 2009

FDA approves once-daily SEROQUEL XR Extended Release Tablets

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment to antidepressants in adults with Major Depressive Disorder (MDD).

4 Dec 2009

Climate change can cause major impact on global mental health

Leading mental health researchers are warning that some of the most important health consequences of climate change will be on mental health, yet this issue is unlikely to be given much attention at the UN climate change conference in Copenhagen next week.

4 Dec 2009

Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

Alkermes, Inc. and Acceleron Pharma, Inc. today announced that Alkermes has licensed a proprietary long-acting Fc fusion technology platform, called the Medifusion™ technology, which is designed to extend the circulating half-life of proteins and peptides.

4 Dec 2009

Schizophrenia News and Research

Latest Schizophrenia News and Research

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Alexza Pharmaceuticals submits its NDA for Staccato loxapine to FDA

ZYPREXA RELPREVV approved by FDA

New biosensors show how schizophrenia drugs alter brain chemistry

Targacept commences TC-5619 Phase 2 study of cognitive dysfunction in schizophrenia

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Eli Lilly provides financial guidance for 2010

CMHA calls to extend Employment Insurance benefits and Pharmacare program for mentally-ill patients

ACNP 2009 to feature research on PTSD, biomarkers for schizophrenia and treatment for gambling addiction

NYSE Amex to delist Cortex Pharmaceuticals

Successful reduction in the levels of aggregated Abeta with GSMs

Psychological trauma leaves a trail of damage in a child's brain, reveal scientists

Two Brown University faculty members receive federal funding for new neuroscience research projects

Janssen-Cilag submits MAA to the European Medicines Agency for paliperidone palmitate

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

FDA approves once-daily SEROQUEL XR Extended Release Tablets

Climate change can cause major impact on global mental health

Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Schizophrenia News and Research

Latest Schizophrenia News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in